GGrantIndex
← Leaderboards

Barry J. Hoffer

University Of Colorado Denver

$147,576
Attributed
$147,576
Total exposure
1
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding mix

By agency

NIH$147,576 · 1

By mechanism

P01$147,576 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Colorado Denver

Same institution · by research overlap

Others in their field

Top investigators on “Laboratory Rat

Research focus

Laboratory RatLaboratory MouseNeurotrophic FactorsStrokeNeuroprotectantsParkinson'S DiseaseNonhuman Therapy EvaluationCerebral Ischemia /HypoxiaGene ExpressionHippocampusSubstantia NigraCorpus StriatumImmunocytochemistryGenetically Modified AnimalsNeurotoxicologyPhenotypeDopamineReceptor ExpressionStroke TherapyGene TherapyLocus CoeruleusNeuropharmacologyAgingTranscription Factor

Grant awards (32)

Studies on CDNF: a new class of neurotrophic proteins$494,841
Z01 · FY2007 · DA · contact PI
Inducible Cre expression through the Rosa 26 locus of recombinant mice$494,841
Z01 · FY2007 · DA · contact PI
The mt-DNA mutator mouse$494,841
Z01 · FY2007 · DA · contact PI
The MitoPark mouse--a new model for Parkinson's Disease$494,841
Z01 · FY2007 · DA · contact PI
The Noradrenergic System Of Aged Gdnf Heterozygous Mice$0
Z01 · FY2004 · DA
The Noradrenergic System Of Aged Gdnf Heterozygous Mice$0
Z01 · FY2003 · DA
siRNAs for Reducing Phenotypic Markers and Studying Gene$0
Z01 · FY2003 · DA
BAC Transgenic Mice Encoding Tau Green Through the Nurr*$0
Z01 · FY2003 · DA
The Noradrenergic System Of Aged Gdnf Heterozygous Mice$0
Z01 · FY2002 · DA
Park2, A Parkinson Candidate Gene, Mapped To The Telomer$0
Z01 · FY2002 · DA
Aav-gdnf Promotes Recovery Of Dopaminergic Phenotype Aft$0
Z01 · FY2002 · DA
Bradykinin receptor agonist facilitates low-dose Cyclosp$0
Z01 · FY2002 · DA
Effects Of Cerebral Ischemia In Mice Deficient In Persep$0
Z01 · FY2002 · DA
Gene Therapy In An Animal Model Of Parkinson$0
Z01 · FY2001 · DA
Characterization Of Gdnf Alpha 1 (gfr Alpha 1) Receptor$0
Z01 · FY2001 · DA
Methamphetamine Exposure And The Nurr1/nurr77 System$0
Z01 · FY2001 · DA
Phenotypic Characterization Of The Nurr77 System$0
Z01 · FY2001 · DA
Intraventricular administration of BMP7 in stroke animal$0
Z01 · FY2001 · DA
Transplantation Therapy For Chronic Stroke$0
Z01 · FY2001 · DA
Blood Brain Barrier Opening With Bradykinin Agonists$0
Z01 · FY2001 · DA
Cannabinoids And Opioids On Synaptic Transmission$0
Z01 · FY2001 · DA
Fetal Kidney Tissue Transplantation And Bmp7$0
Z01 · FY2001 · DA
Gene Therapy And Neuroprotection$0
Z01 · FY2001 · DA
PHARMACOLOGICAL CORRELATES OF AGING IN BRAIN CELL GRAFTS$147,576
P01 · FY2000 · AG
Gene therapy in an animal model of parkinson's disease$0
Z01 · FY2000 · DA
Cannabinoids &opioids on synaptic transmission in nucle$0
Z01 · FY2000 · DA
Blood brain barrier opening with bradykinin agonists$0
Z01 · FY2000 · DA
TRANSPLANTATION THERAPY FOR CHRONIC STROKE$0
Z01 · FY2000 · DA
THERAPEUTIC STRATEGIES FOR STROKE$0
Z01 · FY2000 · DA
PHENOTYPIC CHARACTERIZATION OF THE NURR77 SYSTEM$0
Z01 · FY2000 · DA
METHAMPHETAMINE EXPOSURE AND THE NURR1/NURR77 SYSTEM$0
Z01 · FY2000 · DA
CHARACTERIZATION OF GDNF ALPHA 1 (GFR ALPHA 1) RECEPTOR IN STROKE$0
Z01 · FY2000 · DA